Synthesis and evaluation of radioiodinated estrogens for diagnosis and therapy of male urogenital tumours.


Journal

Organic & biomolecular chemistry
ISSN: 1477-0539
Titre abrégé: Org Biomol Chem
Pays: England
ID NLM: 101154995

Informations de publication

Date de publication:
12 04 2023
Historique:
medline: 13 4 2023
pubmed: 23 3 2023
entrez: 22 3 2023
Statut: epublish

Résumé

The preparation of 24 estrogens, their estrogen receptor (ER) affinity and studies of radioiodinated estrogen binding to ER-positive male bladder tumor cells (HTB9) are described. The estrogens with the highest affinity were selected using fluorescence anisotropy assays. A 2,2,2-trifluoroethyl group at the 11β-position caused particularly promising affinity. (Radio)iodination was performed on the 17α-vinyl group. Binding studies on HTB9 cells revealed picomolar affinities of radioconjugates 19 and 31, indicating promising ability for targeting of urogenital tumors.

Identifiants

pubmed: 36947011
doi: 10.1039/d3ob00114h
doi:

Substances chimiques

Estrogens 0
Estradiol 4TI98Z838E
Receptors, Estrogen 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3090-3095

Auteurs

Feodor Braun (F)

Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937, Cologne, Germany. klaus.schomaecker@uni-koeln.de.

Marcel Jaschinski (M)

Organic Chemistry, Bergische Universität Wuppertal, 42119 Wuppertal, Germany.

Philipp Täger (P)

Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937, Cologne, Germany. klaus.schomaecker@uni-koeln.de.

Verena Marmann (V)

Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937, Cologne, Germany. klaus.schomaecker@uni-koeln.de.

Melanie von Brandenstein (MV)

Clinic and Polyclinic for Urology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.

Barbara Köditz (B)

Clinic and Polyclinic for Urology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.

Thomas Fischer (T)

Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937, Cologne, Germany. klaus.schomaecker@uni-koeln.de.

Sergio Muñoz-Vázquez (S)

Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937, Cologne, Germany. klaus.schomaecker@uni-koeln.de.

Beate Zimmermanns (B)

Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937, Cologne, Germany. klaus.schomaecker@uni-koeln.de.

Markus Dietlein (M)

Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937, Cologne, Germany. klaus.schomaecker@uni-koeln.de.

Ferdinand Sudbrock (F)

Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937, Cologne, Germany. klaus.schomaecker@uni-koeln.de.

Phillip Krapf (P)

Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937, Cologne, Germany. klaus.schomaecker@uni-koeln.de.

Dietmar Fischer (D)

Institutes I & II of Pharmacology, Center of Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.

Axel Heidenreich (A)

Clinic and Polyclinic for Urology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.

Alexander Drzezga (A)

Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937, Cologne, Germany. klaus.schomaecker@uni-koeln.de.

Stefan Kirsch (S)

Organic Chemistry, Bergische Universität Wuppertal, 42119 Wuppertal, Germany.

Markus Pietsch (M)

Institutes I & II of Pharmacology, Center of Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.

Klaus Schomäcker (K)

Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937, Cologne, Germany. klaus.schomaecker@uni-koeln.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH